Thalomid thalidomide: Phase II data; Phase III; marketed to treat moderate to severe erythema nodosum leprosum (ENL)

In a Phase II trial, 200 mg of thalomid plus dexamethasone in 3 day

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE